Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticlePraxis

Rapid recommendations

Updates from 2021 guidelines: part 1

Danielle O’Toole
Canadian Family Physician September 2022; 68 (9) 664-666; DOI: https://doi.org/10.46747/cfp.6809664
Danielle O’Toole
Practising family physician in Academic Family Medicine and Assistant Professor in the Department of Family Medicine at McMaster University in Hamilton, Ont.
MD MSc CCFP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Before physicians can incorporate evolving guideline evidence into their practices, they must first be able to identify salient key updates, which can be buried in lengthy articles. That barrier can delay the integration of novel approaches into clinical care. This article is the first in a 2-part series focusing on key guideline recommendations that were updated or introduced in 2021. Family physicians are always encouraged to appraise each recommendation prior to considering its implementation, as some recommendations are based on low-quality evidence or expert opinion.

Guideline updates

For secondary prevention, the Canadian Cardiovascular Society (CCS) recommends additional non-statin therapy for patients taking maximally tolerated statin therapy and with low-density lipoprotein cholesterol (LDL-C) levels of 1.8 mmol/L or greater (or non–high-density lipoprotein cholesterol [non–HDL-C] levels ≥2.4 mmol/L or apolipoprotein B levels ≥0.7 g/L) (strong recommendation, moderate-quality evidence).1 Lower concentrations of LDL-C are associated with a lower risk of atherosclerotic cardiovascular disease events; specifically, 1 randomized controlled trial (RCT) involving patients with recent ischemic strokes demonstrated a reduction in events in patients assigned lower LDL-C targets of less than 1.8 mmol/L compared with those given LDL-C targets between 2.3 and 2.8 mmol/L.2 Ezetimibe or proprotein convertase subtilisin-kexin type 9 inhibitors in combination with statins reduce major cardiovascular events. Consider proprotein convertase subtilisin-kexin type 9 inhibitors for secondary prevention in a patient taking a maximally tolerated statin and with an LDL-C greater than 2.2 mmol/L, or ezetimibe if LDL-C is between 1.8 and 2.2 mmol/L. This recommendation aligns with the American Heart Association and American College of Cardiology 2018 guideline on the management of blood cholesterol.3

The CCS and the Canadian Heart Rhythm Society (CHRS) suggest the addition of a proton pump inhibitor (PPI) to decrease the risk of gastrointestinal adverse effects for patients with atrial fibrillation who require combination anticoagulant and antiplatelet therapy daily (weak recommendation, moderate-quality evidence).4 There are no RCTs investigating the use of PPIs in patients with atrial fibrillation on oral anticoagulants. However, studies have shown benefits of PPIs for gastroprotection in elderly patients on acetylsalicylic acid with 1 additional risk factor, as well as for patients with stable cardiovascular disease or peripheral arterial disease prescribed combination therapy.

The CCS and the CHRS suggest a blood pressure target of 130/80 mm Hg or less for patients with atrial fibrillation (strength of recommendation and quality of evidence not provided).4 Hypertension Canada guidelines do not list patients with atrial fibrillation as a specific population.5 However, the authors of the 2020 CCS and CHRS guidelines on atrial fibrillation recommend a target blood pressure of 130/80 mm Hg or less at rest and 200/100 mm Hg or less at peak exercise, with angiotensin-converting enzyme inhibitors (ACEIs) being the preferred treatment option.4 This recommendation is consistent with multiple guidelines from other countries.6-9

The CCS and the Canadian Heart Failure Society recommend that patients with heart failure with reduced ejection fraction (HFrEF) be treated with 1 evidence-based medication from each of the following categories: angiotensin receptor–neprilysin inhibitor (ARNI) (or ACEI or angiotensin receptor blocker [ARB]); β-blocker; mineralocorticoid receptor antagonist; and sodium-glucose cotransporter-2 inhibitor (strong recommendation, moderate-quality evidence).10 The previous guideline recommended using an ACEI as the first-line therapy and switching to an ARNI if the patient remained symptomatic on the targeted dose of the ACEI. Although the presence of symptoms is still an indication to start an ARNI, with recent studies showing superiority of ARNIs in the setting of HFrEF,11,12 the guideline’s authors now also recommend an ARNI as first-line therapy in hospitalized patients with HFrEF without previous exposure to either ACEIs or ARBs. Titrate all medications concurrently every 2 to 4 weeks with the goal of attaining targeted doses or maximally tolerated doses within 3 to 6 months of diagnosis. The 2020 guideline update recommended the addition of a sodium-glucose cotransporter-2 inhibitor to guideline-directed medical therapy for HFrEF.13

The Canadian Thoracic Society (CTS) has revised its definition of well-controlled asthma to refer to patients who experience daytime symptoms 2 or fewer days per week and need 2 or fewer reliever doses per week (strength of recommendation and quality of evidence not provided).14,15 In previous guidelines the CTS had described good asthma control as fewer than 4 days per week of daytime symptoms or the need for fewer than 4 doses per week of fast-acting β-agonist.14,15 Asthma control is more than symptom control and considers impact on quality of life, exacerbations, lung function, and inflammatory markers.15 The changes in the 2021 guidelines align the CTS recommendations with the criteria seen in RCTs guiding treatment options14 and with recommendations in other guidelines, such as those of the Global Initiative for Asthma (GINA)16 and the Canadian Paediatric Society,17,18 which define control as symptoms occurring on 8 or fewer days per month. Patients whose asthma is not well controlled should have their treatment escalated.15

The CTS and GINA recommend consideration of inhaled corticosteroid (ICS)–containing treatment in all patients with asthma, especially those at high risk of exacerbation (level B evidence provided in the GINA guideline).15,16 The CTS recommends patients with very mild well-controlled asthma at higher risk for asthma exacerbation have ICS-containing treatment: either daily ICS and short-acting β-agonist as needed (all ages) or inhaled combined budesonide-formoterol as needed for symptoms (for patients 12 years and older).15 Patients with higher risk include those with any history of severe exacerbation (requiring emergency department visits or oral corticosteroids); those with poorly controlled asthma; those who overuse short-acting β-agonists (more than 2 puffers per year); or those who currently are smokers.15 For patients at low risk whose asthma is well controlled, ICS-containing treatment is also an option to improve control and decrease exacerbations.15 Similarly, GINA recommends ICS-containing treatment as above for all patients with asthma, regardless of risk.16 Note that including budesonide-formoterol as an option for reliever therapy is new to both guidelines.

The American Gastroenterological Association and the American Society of Colon and Rectal Surgeons recommend that selected patients with uncomplicated diverticulitis can be treated without antibiotics (strong recommendation based on high-quality evidence, level 1a).19,20 New evidence suggests that diverticulitis is a multifactorial inflammatory reaction.20 Recent studies have shown that antibiotic treatment results in no difference in outcomes among immunocompetent patients, including time to resolution, readmission, complications, or need for surgery, compared with those not treated with antibiotics.19 Antibiotic treatment is advised in patients with complicated diverticulitis and in patients who have uncomplicated diverticulitis as well as comorbidities, frailty, refractory symptoms or vomiting, C-reactive protein levels greater than 140 mg/L, baseline white blood cell counts greater than 15 × 109/L, or fluid collection, as these factors increase the risk of progressing to complicated diverticulitis.19

The Association of Medical Microbiology and Infectious Disease Canada recommends that acute uncomplicated bacterial rhinosinusitis in adults be treated with only 5 to 7 days of antibiotics (strength of recommendation and quality of evidence not provided).21 The previous rhinosinusitis guideline recommended a 10-day course of antibiotics.22 One meta-analysis cited in the newer guideline showed that a duration of 3 to 7 days was as effective as a duration of 6 to 10 days, and a sensitivity analysis of 5 days versus 10 days of antibiotic treatment came to a similar conclusion.23 This update aligns with the 2012 Infectious Diseases Society of America guideline, which recommends 5 to 7 days of antibiotics with a re-evaluation at 3 to 5 days to ensure improvement and no extension of infection.24

Conclusion

This article highlighting key recommendations in cardiac care, respiratory medicine, and gastroenterology is part 1 in a series of articles summarizing guideline updates from 2021. Family physicians are encouraged to appraise these recommendations and explore these updates to advance their knowledge or confirm their current clinical practices.

Notes

We encourage readers to share some of their practice experience: the neat little tricks that solve difficult clinical situations. Praxis articles can be submitted online at http://mc.manuscriptcentral.com/cfp or through the CFP website (https://www.cfp.ca) under “Authors and Reviewers.”

Footnotes

  • Competing interests

    None declared

  • Copyright © 2022 the College of Family Physicians of Canada

References

  1. 1.↵
    1. Pearson GJ,
    2. Thanassoulis G,
    3. Anderson TJ,
    4. Barry AR,
    5. Couture P,
    6. Dayan N, et al.
    2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol 2021;37(8):1129–50. Epub 2021 Mar 26.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Amarenco P,
    2. Kim JS,
    3. Labreuche J,
    4. Charles H,
    5. Abtan J,
    6. Béjot Y, et al.
    A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med 2020;382(1):9–19. Epub 2019 Nov 18.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Grundy SM,
    2. Stone NJ,
    3. Bailey AL,
    4. Beam C,
    5. Birtcher KK,
    6. Blumenthal RS, et al.
    2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;73(24):e285–350. Epub 2018 Nov 10. Erratum in: J Am Coll Cardiol 2019;73(24):3237-41.
    OpenUrlFREE Full Text
  4. 4.↵
    1. Andrade JG,
    2. Aguilar M,
    3. Atzema C,
    4. Bell A,
    5. Cairns JA,
    6. Cheung CC, et al.
    The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Can J Cardiol 2020;36(12):1847–948. Epub 2020 Oct 22.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Rabi DM,
    2. McBrien KA,
    3. Sapir-Pichhadze R,
    4. Nakhla M,
    5. Ahmed SB,
    6. Dumanski SM, et al.
    Hypertension Canada’s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol 2020;36(5):596–624.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Umemura S,
    2. Arima H,
    3. Arima S,
    4. Asayama K,
    5. Dohi Y,
    6. Hirooka Y, et al.
    The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res 2019;42(9):1235–481.
    OpenUrlCrossRefPubMed
  7. 7.
    1. Whelton PK,
    2. Carey RM,
    3. Aronow WS,
    4. Casey DE Jr,
    5. Collins KJ,
    6. Dennison Himmelfarb C, et al.
    2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71(6):1269–324. Epub 2017 Nov 13. Errata in: Hypertension 2018;71(6):e136-9, Hypertension 2018;72(3):e33.
    OpenUrlCrossRefPubMed
  8. 8.
    1. Williams B,
    2. Mancia G,
    3. Spiering W,
    4. Agabiti Rosei E,
    5. Azizi M,
    6. Burnier M, et al.
    2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018;39(33):3021–104. Erratum in: Eur Heart J 2019;40(5):475.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Lee HY,
    2. Shin J,
    3. Kim GH,
    4. Park S,
    5. Ihm SH,
    6. Kim HC, et al.
    2018 Korean Society of Hypertension guidelines for the management of hypertension: part II—diagnosis and treatment of hypertension. Clin Hypertens 2019;25:20.
    OpenUrlPubMed
  10. 10.↵
    1. McDonald M,
    2. Virani S,
    3. Chan M,
    4. Ducharme A,
    5. Ezekowitz JA,
    6. Giannetti N, et al.
    CCS/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol 2021;37(4):531–46.
    OpenUrlCrossRef
  11. 11.↵
    1. McMurray JJV,
    2. Packer M,
    3. Desai AS,
    4. Gong J,
    5. Lefkowitz MP,
    6. Rizkala AR, et al.
    Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371(11):993–1004. Epub 2014 Aug 30.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Velazquez EJ,
    2. Morrow DA,
    3. DeVore AD,
    4. Duffy CI,
    5. Ambrosy AP,
    6. McCague K, et al.
    Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019;380(6):539–48. Epub 2018 Nov 11. Erratum in: N Engl J Med 2019;380(11):1090. Epub 2019 Feb 15.
    OpenUrlPubMed
  13. 13.↵
    1. O’Meara E,
    2. McDonald M,
    3. Chan M,
    4. Ducharme A,
    5. Ezekowitz JA,
    6. Giannetti N, et al.
    CCS/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis. Can J Cardiol 2020;36(2):159–69.
    OpenUrlPubMed
  14. 14.↵
    1. Yang CL,
    2. Hicks EA,
    3. Mitchell P,
    4. Reisman J,
    5. Podgers D,
    6. Hayward KM, et al.
    2021 Canadian Thoracic Society guideline—a focused update on the management of very mild and mild asthma. Can J Respir Crit Care Sleep Med 2021;5(4):205–45.
    OpenUrlCrossRef
  15. 15.↵
    1. Yang CL,
    2. Hicks EA,
    3. Mitchell P,
    4. Reisman J,
    5. Podgers D,
    6. Hayward KM, et al.
    Canadian Thoracic Society 2021 guideline update: diagnosis and management of asthma in preschoolers, children and adults. Can J Respir Crit Care Sleep Med 2021;5(6):348–61.
    OpenUrl
  16. 16.↵
    1. Reddel HK,
    2. Bacharier LB,
    3. Bateman ED,
    4. Brightling CE,
    5. Brusselle GG,
    6. Buhl R, et al.
    Global Initiative for Asthma strategy 2021: executive summary and rationale for key changes. Am J Respir Crit Care Med 2022;205(1):17–35.
    OpenUrl
  17. 17.↵
    1. Trottier ED,
    2. Chan K,
    3. Allain D,
    4. Chauvin-Kimoff L.
    Managing an acute asthma exacerbation in children. Paediatr Child Health 2021;26(7):438–9.
    OpenUrl
  18. 18.↵
    1. Ducharme FM,
    2. Dell SD,
    3. Radhakrishnan D,
    4. Grad RM,
    5. Watson WT,
    6. Yang CL, et al.
    Diagnosis and management of asthma in preschoolers: a Canadian Thoracic Society and Canadian Paediatric Society position paper. Paediatr Child Health 2015;20(7):353–71.
    OpenUrl
  19. 19.↵
    1. Peery AF,
    2. Shaukat A,
    3. Strate LL.
    AGA clinical practice update on medical management of colonic diverticulitis: expert review. Gastroenterology 2021;160(3):906–11.e1. Epub 2020 Dec 3.
    OpenUrl
  20. 20.↵
    1. Hall J,
    2. Hardiman K,
    3. Lee S,
    4. Lightner A,
    5. Stocchi L,
    6. Paquette IM, et al.
    The American Society of Colon and Rectal Surgeons clinical practice guidelines for the treatment of left-sided colonic diverticulitis. Dis Colon Rectum 2020;63(6):728–47.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Grant J,
    2. Le Saux N; members of the Antimicrobial Stewardship and Resistance Committee of the Association of Medical Microbiology and Infectious Disease Canada
    . Duration of antibiotic therapy for common infections. Off J Assoc Med Microbiol Infect Dis Can 2021;6(3):181–97.
    OpenUrl
  22. 22.↵
    1. Kaplan A.
    Canadian guidelines for acute bacterial rhinosinusitis. Clinical summary. Can Fam Physician 2014;60:227–34 (Eng), e149-56 (Fr).
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Falagas ME,
    2. Karageorgopoulos DE,
    3. Grammatikos AP,
    4. Matthaiou DK.
    Effectiveness and safety of short vs. long duration of antibiotic therapy for acute bacterial sinusitis: a meta-analysis of randomized trials. Br J Clin Pharmacol 2009;67(2):161–71. Epub 2008 Sep 19.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Chow AW,
    2. Benninger MS,
    3. Brook I,
    4. Brozek JL,
    5. Goldstein EJC,
    6. Hicks LA, et al.
    IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012;54(8):e72–112. Epub 2012 Mar 20.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 68 (9)
Canadian Family Physician
Vol. 68, Issue 9
1 Sep 2022
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Rapid recommendations
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rapid recommendations
Danielle O’Toole
Canadian Family Physician Sep 2022, 68 (9) 664-666; DOI: 10.46747/cfp.6809664

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Rapid recommendations
Danielle O’Toole
Canadian Family Physician Sep 2022, 68 (9) 664-666; DOI: 10.46747/cfp.6809664
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Guideline updates
    • Conclusion
    • Notes
    • Footnotes
    • References
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Rapid recommendations: Updates from 2021 guidelines: part 2
  • Google Scholar

More in this TOC Section

  • Éponge à haut rebond comme outil de simulation d’une suture périnéale
  • High-rebound sponge as a simulation tool for perineal suture
  • Assessment and management of disability due to mental disorders
Show more Praxis

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire